Your browser doesn't support javascript.
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.
Garcia-Valtanen, Pablo; Hope, Christopher M; Masavuli, Makutiro G; Yeow, Arthur Eng Lip; Balachandran, Harikrishnan; Mekonnen, Zelalem A; Al-Delfi, Zahraa; Abayasingam, Arunasingam; Agapiou, David; Stella, Alberto Ospina; Aggarwal, Anupriya; Bouras, George; Gummow, Jason; Ferguson, Catherine; O'Connor, Stephanie; McCartney, Erin M; Lynn, David J; Maddern, Guy; Gowans, Eric J; Reddi, Benjamin A J; Shaw, David; Kok-Lim, Chuan; Beard, Michael R; Weiskopf, Daniela; Sette, Alessandro; Turville, Stuart G; Bull, Rowena A; Barry, Simon C; Grubor-Bauk, Branka.
  • Garcia-Valtanen P; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
  • Hope CM; Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia; Women's and Children's Health Network, North Adelaide, SA, Australia.
  • Masavuli MG; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
  • Yeow AEL; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
  • Balachandran H; School of Medical Sciences, Faculty of Medicine, UNSW, Australia, Sydney, NSW, Australia.
  • Mekonnen ZA; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
  • Al-Delfi Z; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
  • Abayasingam A; School of Medical Sciences, Faculty of Medicine, UNSW, Australia, Sydney, NSW, Australia.
  • Agapiou D; School of Medical Sciences, Faculty of Medicine, UNSW, Australia, Sydney, NSW, Australia.
  • Stella AO; The Kirby Institute, The University of New South Wales, Sydney, NSW, Australia.
  • Aggarwal A; The Kirby Institute, The University of New South Wales, Sydney, NSW, Australia.
  • Bouras G; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; The Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide and the Basil Hetzel Institute for Translational Health Research, Central Adelaide Local Hea
  • Gummow J; Gene Silencing and Expression Core Facility, Adelaide Health and Medical Sciences, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.
  • Ferguson C; Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
  • O'Connor S; Intensive Care Unit, Royal Adelaide Hospital, Central Adelaide Local Health Network and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • McCartney EM; Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
  • Lynn DJ; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • Maddern G; Discipline of Surgery, The University of Adelaide, Adelaide, SA 5000, Australia.
  • Gowans EJ; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
  • Reddi BAJ; Intensive Care Unit, Royal Adelaide Hospital, Central Adelaide Local Health Network and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • Shaw D; Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
  • Kok-Lim C; Gene Silencing and Expression Core Facility, Adelaide Health and Medical Sciences, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia; Microbiology and Infectious Diseases Department, SA Pathology, Adelaide, SA, Australia; Research Centre for Infectious Diseases, School of
  • Beard MR; Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia.
  • Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.
  • Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.
  • Turville SG; The Kirby Institute, The University of New South Wales, Sydney, NSW, Australia.
  • Bull RA; School of Medical Sciences, Faculty of Medicine, UNSW, Australia, Sydney, NSW, Australia.
  • Barry SC; Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia; Women's and Children's Health Network, North Adelaide, SA, Australia. Electronic address: simon.barry@adelaide.edu.au.
  • Grubor-Bauk B; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia. Electronic address: branka.grubor@adelaide.edu.au.
Cell Rep Med ; 3(6): 100651, 2022 06 21.
Article in English | MEDLINE | ID: covidwho-1873330
ABSTRACT
Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100651

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100651